Canine Osteosarcoma Cell Line (OSCA-8)

Canine Osteosarcoma Cell Line (OSCA-8)

OSCA-8 is a canine osteosarcoma cell line derived from a left-shoulder tumor of a 1-year old intact male Rottweiler.

Highlights:

  • Grows in vitro and forms orthotopic and heterotopic tumor xenografts in immunodeficient mice
  • Gene expression profile is consistent with that observed in the most aggressive molecular phenotype of osteosarcoma

Osteosarcomas are aggressive malignant neoplasia that arise from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and exhibit osteoblastic differentiation and produce malignant osteoid.

From the laboratory of Jaime F. Modiano, VMD, PhD, University Minnesota, Twin Cities.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
EMN001-FP
Canine Osteosarcoma Cell Line (OSCA-8)
1 vial In stock
Regular Price:$640.00
On Sale:

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications

Product Type: Cell Line
Name: OSCA-8
Cell Type: Osteosarcoma
Accession ID: CVCL_L405
Organism: Dog
Source: Bone (humerus)
Morphology: Spindle
Biosafety Level: 2
Growth Conditions: DMEM, 10mM HEPES, 10% FBS, 100ug/mL Primocin
Cryopreservation: 90%FBS/10% DMSO
Mycoplasma Tested: Yes
Storage: Liquid nitrogen
Shipped: Dry ice

Documentation

PDF OSCA Cell Line Protocol

PDF Canine Cell Line Authentication Data

Provider
From the laboratory of Jaime F. Modiano, VMD, PhD, University Minnesota, Twin Cities.
References
  1. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. Characterization of STAT3 activation and expression in canine and human osteosarcoma.BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.
  2. McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660.
  3. Liao AT, McCleese J, Kamerling S, Christensen J, London CA. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma. Vet Comp Oncol. 2007 Sep;5(3):177-96. doi: 10.1111/j.1476-5829.2007.00137.x.
  4. McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res. 2010 Jul;71(7):799-808. doi: 10.2460/ajvr.71.7.799.
  5. Wolfe TD, Pillai SP, Hildreth BE 3rd, Lanigan LG, Martin CK, Werbeck JL, Rosol TJ. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis. 2011 Apr;28(4):377-89. doi: 10.1007/s10585-011-9377-9. Epub 2011 Mar 4.
  6. Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112.
  7. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125.
  8. Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, Subramanian S, Breen M, Modiano JF. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. Epub 2011 May 15.
  9. London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3.
  10. McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA. Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol. 2013 Jun;11(2):124-39. doi: 10.1111/j.1476-5829.2011.00309.x. Epub 2011 Dec 8.
  11. Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, Graef AJ, Steer CJ, Modiano JF, Subramanian S. Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One. 2012;7(9):e43720. doi: 10.1371/journal.pone.0043720. Epub 2012 Sep 5.
  12. Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.
  13. Wells JW, Evans CH, Scott MC, Rütgen BC, O'Brien TD, Modiano JF, Cvetkovic G, Tepic S. Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation. PLoS One. 2013;8(1):e54464. doi: 10.1371/journal.pone.0054464. Epub 2013 Jan 24.
  14. Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6. PubMed PMID: 28109246; PubMed Central PMCID: PMC5251323.
  15. Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF. Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech. 2016 Dec 1;9(12):1435-1444. Epub 2016 Nov 3. PubMed PMID: 27874835; PubMed Central PMCID: PMC5200896.
  16. Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC, London CA. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer. 2016 Oct 10;16(1):784. PubMed PMID: 27724924; PubMed Central PMCID: PMC5057229.
  17. Scott MC, Sarver AL, Tomiyasu H, Cornax I, Van Etten J, Varshney J, O'Sullivan MG, Subramanian S, Modiano JF. Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma. J Biol Chem. 2015 Nov 20;290(47):28070-83. doi: 10.1074/jbc.M115.679696. Epub 2015 Sep 16. PubMed PMID: 26378234; PubMed Central PMCID: PMC4653667.
  18. Im KS, Graef AJ, Breen M, Lindblad-Toh K, Modiano JF, Kim JH. Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma. Vet Comp Oncol. 2017 Jun;15(2):315-327. doi: 10.1111/vco.12165. Epub 2015 Sep 3. PubMed PMID: 26337509.
  19. Lin W, Modiano JF, Ito D. Stage-specific embryonic antigen: determining expression in canine glioblastoma, melanoma, and mammary cancer cells. J Vet Sci. 2017 Mar 30;18(1):101-104. doi: 10.4142/jvs.2017.18.1.101. PubMed PMID: 27456773; PubMed Central PMCID: PMC5366293.
  20. Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression and survival in osteosarcoma. Cancer Res. 2017 Oct 24. pii: canres.0576.2017. View Article
  21. Patatsos K, Shekhar TM, Hawkins CJ. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. Vet Comp Oncol. 2018 Jul 12. View Article
  22. Musser ML, Mahaffey AL, Fath MA, et al. In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs. Front Vet Sci. 2019;6:385. Published 2019 Nov 7. View article

If you publish research with this product, please let us know so we can cite your paper.